

Lysergic Acid Diethylamide (LSD)

Selected References:

- Aase JM, et al. 1970. Children of mothers who took LSD in pregnancy. *Lancet*; 1:100-1.
- Alexander GJ, et al. 1970. Lysergic acid diethylamide intake in pregnancy: fetal damage in rats. *J Pharmacol Exp Ther*; 173(1):48-59.
- Baquiran M, et al. 2023. Lysergic acid diethylamide toxicity. [Updated 2023 Dec 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK553216/>
- Cohen MM, et al. 1968. The effect of LSD-25 on the chromosomes of children exposed in utero. *Pediat Res* 2:486-492.
- Das, Saibal et al. 2016. Lysergic acid diethylamide: a drug of 'use'?. *Therapeutic advances in psychopharmacology*; 6(3):214-28.
- Fabro S, Sieber SM. 1968. Is lysergide a teratogen? *Lancet* 1(7543):639.
- Fuentes Jet al. 2020. Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. *Frontiers in Psychiatry*; 10:943.
- Jacobson CB, Berlin CM. 1972. Possible reproductive detriment in LSD users. *JAMA* 222(11):1367-1373.
- Haden, M, & Woods, B. 2020. LSD overdoses: three case reports. *Journal of Studies on Alcohol and Drugs*; 81(1), 115-118.
- Long SY. 1972. Does LSD induce chromosomal damage and malformations? A review of the literature. *Teratology*; 6(1):75-90.
- McElhatton PR. 2000. Fetal effects of substances of abuse. *J Toxicol Clin Toxicol*; 38:194-5.
- McGlothlin WH, et al. 1970. Effect of LSD on human pregnancy. *JAMA*.1; 212(9):1483-7.
- Mueller, B. A., Daling, J. R., Weiss, N. S., & Moore, D. E. (1990). Recreational drug use and the risk of primary infertility. *Epidemiology (Cambridge, Mass.)*, 1(3), 195-200.
- Papac DI and Foltz RL. 1990. Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. *J Anal Toxicol*; 14(3):189-90.
- Robinson JT, et al. 1974. Chromosome aberrations and LSD. A controlled study in 50 psychiatric patients. *J Psychiatry*. 125(0):238-44.
- Zellweger H, et al. 1967. Is lysergic-acid diethylamide a teratogen? *Lancet*; 2(7525):1066-1068.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.mothertobaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Lysergic Acid Diethylamide (LSD)

Selected References:

- Alwan S, et al. 2016. Safety of selective serotonin reuptake inhibitors in pregnancy: a review of current evidence. *CNS Drugs*, 30(6):499-515.
- Andersen JT, et al. 2014. Exposure to selective serotonin reuptake inhibitors in early pregnancy and the risk of miscarriage. *Obstet Gynecol*, 124:655-661.
- Bandoli G, et al. 2020. Prenatal antidepressant use and risk of adverse neonatal outcomes. *Pediatrics*, 146(1):e20192493.
- Berard A, et al. 2017. Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort. *BMJ Open*, 7:e013372.
- Bonari L, et al. 2004. Perinatal risks of untreated depression during pregnancy. *Can J Psychiatry*, 49(11):726-735.
- Burch KJ and Wells BG. 1992. Fluoxetine/norfluoxetine concentrations in human milk. *Pediatrics*, 89:676-677.
- Chambers CD, et al. 1999. Weight gain in infants breastfed by mothers who take fluoxetine. *Pediatrics*, 104(5):11-15.
- Chambers C, et al. 2006. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. *N Engl J Med*, 354(6):579-587.
- Desautay P, Eude LG, Dreyfus M, Alexandre C, Fedrizzi S, Alexandre J, Uguz F, Guénolé F. Benefits and Risks of Antidepressant Drugs During Pregnancy: A Systematic Review of Meta-analyses. *Paediatr Drugs*. 2023 May;25(3):247-265. doi: 10.1007/s40272-023-00561-2. Epub 2023 Feb 28. PMID: 36853497.
- Diav-Citrin O, et al. 2008. Paroxetine and fluoxetine in pregnancy: a prospective, multicenter, controlled, observational study. *Br J Clin Pharmacol*, 66(5):695-705.
- Gao SY, et al. 2017. Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies. *Br J Clin Pharmacol*, 83(10):2134-2147.
- Goldstein DJ, Marvel DE. 1993. Psychotropic medications during pregnancy: risk to the fetus. *JAMA*, 270:2177.
- Goldstein DJ, et al. 1997. Effects of first-trimester fluoxetine exposure on the newborn. *Obstet Gynecol*, 89:713-8.
- Grigoriadis S, et al. 2013. The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. *J Clin Psychiatry*, 74(4):e309-20.
- Grigoriadis S, et al. 2019. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta-analysis. *J Clin Psychiatry*, 80(4):18r12412.
- Huybrechts KF, et al. 2014. Antidepressant use in pregnancy and the risk of cardiac defects. *N Engl J Med*, 370:2397-2407.
- Huybrechts KF, et al. 2015. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. *JAMA*, 313(21):2142-2151.
- Isenberg KE. 1990. Excretion of fluoxetine in human breast milk. *J Clin Psychiatry*, 51:169.
- Jimenez-Solem E et al. 2012. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. *BMJ*, 2:e001148.
- Jordan S, et al. 2019. Antidepressant prescriptions, discontinuation, depression, and perinatal outcomes, including breastfeeding: a population cohort analysis. *PLoS One*, 14(11):e0225133.
- Kaplan et al. 2017. Maternal SSRI discontinuation, use, psychiatric disorder and the risk of autism in children: a

meta-analysis of cohort studies. *Br J Clin Pharmacol*, 83(12):2798-2806.

- Kieviet N, et al. 2015. Risk factors for poor neonatal adaptation after exposure to antidepressants in utero. *Acta Paediatr*, 104(4):384-391.
- Kristensen JH, et al. 1999. Distribution and excretion of fluoxetine and norfluoxetine in human milk. *Br J Clin Pharmacol*, 48(4):521-527.
- Levinson-Castiel R, et al. 2006. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. *Arch Pediatr Adolesc Med*, 160:173-176.
- Louik C, et al. 2007. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. *N Engl J Med*, 356:2675-2683.
- Lusskin SI, et al. 2018. Pharmacotherapy for Perinatal Depression. *Clin Obstet Gynecol*, 61(3):544-561.
- Masarwa R, et al. 2019. Prenatal exposure to selective serotonin reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis. *Am J Obstet Gynecol*, 220(1):57.e1-57.e13.
- Morris R, Matthes J. 2015. Serotonin syndrome in a breast-fed neonate. *BMJ Case Rep*, doi:10.1136/bcr-2015-209418.
- Moses-Kolko, E.L. et al. 2005. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. Literature review and implications for clinical applications. *J Am Med Assoc*, 293: 2372-2383.
- Nulman I, et al. 1997. Neurodevelopment of children exposed in utero to antidepressant drugs. *NEJM*, 336(4):258-262.
- Nulman I, et al. 2002. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. *Am J Psychiatry*, 159(11):1889-1895.
- Ornoy A. 2017. Neurobehavioral risks of SSRIs in pregnancy: Comparing human and animal data. *Reprod Toxicol*, 72:191-200.
- PD-Rx Pharmaceuticals, Inc. 2025. *Fluoxetine capsules: Prescribing information*. DailyMed. [Accessed August 2026].
<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d26f7450-7650-43df-a63b-1fe2472882a9&type=display>
- Pedersen LH, et al. 2009. Selective serotonin inhibitors in pregnancy and congenital malformations: population based cohort study. *BMJ*, 339:b3569.
- Rampono J, et al. 2009. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. *Pharmacopsychiatry*, 42(3):95-100.
- Ruchkin V, Martin A. 2005. SSRIs and the developing brain. *Lancet*, 365:451-453.
- Sanz E, et al. 2005. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. *Lancet*, 365:482-487.
- Sjaarda LS et al. 2020. Urinary selective serotonin reuptake inhibitors across critical windows of pregnancy establishment: a prospective cohort study of fecundability and pregnancy loss. *Fertil Steril*, 114(6):1278-1287.
- Strain, SL. 1994. Fluoxetine-initiated ovulatory cycles in two clomiphene-resistant women. *J Am J Psychiatry*, 151(4):620.
- Salisbury AL, et al. 2016. The roles of maternal depression, serotonin reuptake inhibitor treatment, and concomitant benzodiazepine use on infant neurobehavioral functioning over the first postnatal month. *Am J Psychiatry*, 173(2):147-157.
- Sylvester C, et al. 2019. selective serotonin reuptake inhibitors and fertility: considerations for couples trying to conceive. *Harv Rev Psychiatry*, 27(2):108-118.
- Taddio A, Ito S, and Koren G. 1996. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breastmilk. *J Clin Pharmacol*, 36(1):42-47.
- Vaidya R, et al. 2024. Non epileptiform abnormal neurologic signs in newborns following in-utero psychotropic medication exposure. *Journal of Neonatal-Perinatal Medicine*. 17(5):717-722.
- Wang S, et al. 2015. Selective serotonin reuptake inhibitors (SSRIs) and the risk of congenital heart defects: a meta-analysis of prospective cohort studies. *Journal of the American Heart Association*, 4(5)e001681.

- Wen SW, et al. 2006. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol, 194(4):961-966.
- Wisner KL, Avram MJ, George AL Jr, Abramova TV, Yang A, Caritis SN, Costantine MM, Stika CS. Concentrations of Fluoxetine Enantiomers Decline During Pregnancy and Increase After Birth. J Clin Psychopharmacol. 2024 Mar-Apr 01;44(2):100-106.
- Yang F, et al. 2017. Risk of autism spectrum disorder in offspring following paternal use of selective serotonin reuptake inhibitors before conception: a population-based cohort study. BMJ Open, 7(12):e016368.
- Yang F, et al. 2018. Prenatal paternal selective serotonin reuptake inhibitors use and risk of ADHD in offspring. Pediatrics, 141(1):e20171081.
- Yonkers KA, et al. 2009. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Obstet Gynecol, 114(3):703-713.
- Yoshida, K, et al. 1998. Fluoxetine in breastmilk and developmental outcome of breastfed infants. Br J Psychiatry, 172:175-178. Pregnant Women with Suspected or Confirmed Influenza. Obstet Gyn, 132(4):e169-e173.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Lysergic Acid Diethylamide (LSD)

Selected References:

- Akbari M, et al. 2013. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis, 19(1):15-22.
- Alami Z, et al. 2018. Pregnancy outcome following in utero exposure to azathioprine: a French comparative observational study. Therapie, 73(3):199-207.
- Alshwairikh LA, Zeneb B. 2022. A 25-year-old Saudi woman with a 2-year history of antisyntetase syndrome with interstitial lung disease who commenced azathioprine treatment in the third trimester of pregnancy and

had a successful birth at term. *Am J Case Rep*, 7:23:e936833.

- Balevic S, et al. 2024. Azathioprine metabolite levels and outcomes during pregnancies with rheumatic disease. *Lupus Sci Med*, 11(1):e0011036.
- Casanova MJ, et al. 2013. Safety of thiopurines and anti-TNF-alpha drugs during pregnancy in patients with inflammatory bowel disease. *Am J Gastroenterol*, 108(3):433-440.
- Christensen LA, et al. 2008. Azathioprine treatment during lactation. *Aliment Pharmacol Ther*, 28(10):1209-1213.
- Davison JM et al. 1985. Maternal azathioprine therapy and depressed haematopoiesis in the babies of renal allograft patients. *Br J Obstet Gynaecol*, 92:233-239.
- de Meij TG, et al. 2013. Dutch Initiative on crohn and colitis. Long-term follow-up of children exposed intrauterine to maternal thiopurine therapy during pregnancy in females with inflammatory bowel disease. *Aliment Pharmacol Ther*, 38(1):38-43.
- Dejaco C, et al. 2001. Azathioprine treatment and male fertility in inflammatory bowel disease. *Gastroenterology*, 121:1048-53.
- Francella A, et al. 2003. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. *Gastroenterology*, 124(1):9-17.
- Friedman S, et al. 2017. Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring: a nationwide cohort study. *Reproductive Toxicology*, 73:196-200.
- Götestam Skorpen C, et al. 2016. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. *Ann Rheum Dis*, 75(5):795-810.
- Goldstein LH, et al. 2007. Pregnancy outcome of women exposed to azathioprine during pregnancy. *Birth Defects Res A Clin Mol Teratol*, 79(10):696-701.
- Hoeltzenbein M, et al. 2012. Pregnancy outcome after paternal exposure to azathioprine/6-mercaptopurine. *Reprod Toxicol*, 34(3):364-369.
- Ikram N, et al. 2021. Breastfeeding in women with rheumatic diseases. *Lupus Sci Med*, 8(1):e000491.
- Khedr L, Ekram M. 2024. *Eur J Case Rep Intern Med*, 11(4):004385.
- Kinnucan J, Kane S. 2021. Editorial: thiopurines but not anti-TNF monotherapy are linked to worse pregnancy outcomes in a large population-based study. *Aliment Pharmacol Ther*, 54(3):343-344.
- Langagergaard V, et al. 2007. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. *Aliment Pharmacol Ther*, 25(1):73-81.
- Matalon ST, et al. 2004. Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). *Reprod Toxicol*, 18(2):219-230.
- Matarazzo L, et al. 2021. Pregnancy outcome in women with childhood onset autoimmune hepatitis and autoimmune sclerosing cholangitis on long-term immunosuppressive treatment. *Eur J Obstet Gynecol Reprod Biol*, 268:7-11.
- Moretti ME et al. 2006. Breast-feeding during maternal use of azathioprine. *Ann Pharmacother*, 40(12):2269-2272.
- Motta M, et al. 2007. Immune system development in infants born to mothers with autoimmune disease, exposed in utero to immunosuppressive agents. *Am J Perinatol*, 24(8):441-447.
- Myer A, et al. 2021. Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018. *Aliment Pharmacol Ther*, 54(3):302-311.
- Nørgård B, et al. 2004. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception. *Aliment Pharmacol Ther*, 19(6):679-685.
- Reynolds JA, et al. 2023. Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. *Rheumatology (Oxford)*, 62(3):1124-1135.
- Skejo C, et al. 2024. Early onset sepsis and lobar pneumonia in a newborn exposed in utero to Ustekinumab and

azathioprine. Inflamm Bowel Dis, 30(2):314-315.

- Wolf MF, et al. 2023. Azathioprine and 6-mercaptopurine-induced intrahepatic cholestasis of pregnancy: case report and review of literature: Taiwan J Obstet Gynecol, 63(5):761-764.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Lysergic Acid Diethylamide (LSD)

Selected References:

- Adank MC, et al. 2019. Is maternal lipid profile in early pregnancy associated with pregnancy complications and blood pressure in pregnancy and long term postpartum?. Obstet Gynecol; 221(2): 150-e1.
- Agarwala A, et al. 2024. Dyslipidemia management in women of reproductive potential: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol; 18(5):e664-e684.
- Arias A, et al. 2022. Implications of High-Density Cholesterol Metabolism for Oocyte Biology and Female Fertility. Frontiers in cell and developmental biology; 10:941539.
- Berge LN, et al. 1996. Pregnancy related changes in some cardiovascular risk factors. Acta Obstet Gynecol Scand; 75:439-442.
- Brizzi P, et al. 1999. Lipoprotein metabolism during normal pregnancy. Obstet Gynecol; 181(2):430-34.
- Christensen S, et al. 2023. Maternal inflammatory, lipid and metabolic markers and associations with birth and breastfeeding outcomes. Frontiers in nutrition; 10:1223753.
- Christopher BA, et al. 2019. Evaluation and management of lipid disorders: summary. Clinical Updates in Women's Health Care. American College of Obstetricians and Gynecologists. Obstet Gynecol; 133:609.
- Cristodoro M, et al. 2024. Dietary Patterns and Fertility. Biology; 13(2),131.
- Dal Pino B, et al. 2026. Severe familial hypercholesterolemia and pregnancy: handle with care. Nutr Metab Cardiovasc Dis; 104767.
- de Oliveira AA, et al. 2026. Excessive hypercholesterolaemia during pregnancy as a risk factor for endothelial

dysfunction in pre-eclampsia. *J Physiol*; 604(11):4302-4317.

- France M, et al. 2016. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom. *Atherosclerosis*; 255:128-139.
- Graham DF, et al. 2021. Management of familial hypercholesterolemia in pregnancy. *Curr Opin Lipidol*; 32(6):370-377.
- Goharkhay N, et al. 2008. Maternal hypercholesterolemia leads to activation of endogenous cholesterol synthesis in the offspring. *Amer J Obstet Gynecol*; 199(3): 273-e1.
- Goldberg AC et al. 2011. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol*; 5(3 Suppl):S1-8.
- Gootjes D, et al. 2022. Maternal lipid profile in pregnancy and embryonic size: a population-based prospective cohort study. *BMC pregnancy and childbirth*; 22(1):333.
- Grandi SM, et al. 2026. Elevated lipid levels and altered semen parameters in men of couples seeking fertility care. *Am J Epidemiol*; May 12:kwag103.
- Holven KB, et al. 2026. Challenges in the care of women with familial hypercholesterolaemia during the reproductive period – current evidence and practical guidance. *Atherosclerosis*; 415:120679.
- Jiang S et al. 2017. Maternal dyslipidemia during pregnancy may increase the risk of preterm birth: A meta-analysis. *Taiwan J Obstet Gynecol*; 56(1):9-15.
- Kaneko K, et al. 2022. High Maternal Total Cholesterol Is Associated With No-Catch-up Growth in Full-Term SGA Infants: The Japan Environment and Children's Study. *Frontiers in endocrinology*; 13:939366.
- Klevmoen M, et al. 2021. Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia. *Atherosclerosis*; 335:8-15.
- Liberis A, et al. 2021. Lipid Disorders in Pregnancy. *Curr Pharm Des*. 27(36):3804-3807.
- Mauri M, et al. 2021. Dyslipemias and pregnancy, an update. *Clin Investig Arterioscler*. 33(1):41-52.
- Moayeri M, et al. 2017. Maternal lipid profile and the relation with spontaneous preterm delivery: a systematic review. *Arch Gynecol Obstet*; 295(2):313-323.
- Mulder J, et al. 2024. Lipid metabolism during pregnancy: consequences for mother and child. *Current opinion in lipidology*; 35(3): 133-140.
- Napoli C, et al. 1999. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. *Lancet*; 354(9186): 1234-41.
- Nasioudis D, et al. 2018. Dyslipidemia in pregnancy and maternal-fetal outcome. *Minerva ginecologica*. 71(2):155-62.
- Ogura et al. 2016. Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion. *Atherosclerosis*; 254:179-183.
- Omolaoye T, et al. 2022. Statins and Male Fertility: Is There a Cause for Concern?. *Toxics*; 10(10):627.
- Pugh et al. 2017. Preconception maternal lipoprotein levels in relation to fecundability. *Hum Reprod*. 15:1-9.
- Pushpendra A, et al. 2015. Hyper-lipidemia and male fertility: a critical review of literature. *Andrology*; 4(2).
- Schisterman EF, et al. 2014. Lipid concentrations and couple fecundity: the LIFE study. *J Clin Endocrinol Metab*; 99(8):2786-94.
- Schisterman EF, et al. 2014. Lipid concentrations and semen quality: the LIFE study. *Andrology*; 2(3):408-15.
- Sharami SH, 2019. The relationship of hyperlipidemia with maternal and neonatal outcomes in pregnancy: A cross-sectional study. *International Journal of Reproductive BioMedicine*; 17(10): 739.
- Smith CJ, et al. 2018. Maternal dyslipidemia and risk for preterm birth. *PloS one*; 13(12): e0209579.
- Toleikyte I, et al. 2011. Pregnancy outcomes in familial hypercholesterolemia: a registry-based study. *Circulation*; 124(15):1606-14.
- Varnier NA, et al. 2015. Coronary artery disease secondary to familial hypercholesterolaemia: An infrequent cause of increasingly common pregnancy co-morbidity. *Obstet Med*; 8(3):152-4.

- Vrijkotte TG, et al. 2012. Maternal lipid profile during early pregnancy and pregnancy complications and outcomes: the ABCD study. *The Journal of Clinical Endocrinology & Metabolism*; 97(11): 3917-25.
- Wang C, et al. 2016. The associations between early pregnancy lipid profiles and pregnancy outcomes. *J Perinatol*. 37(2):127-133.
- Whitfield M, et al. 2015. Posttesticular sperm maturation, infertility, and hypercholesterolemia. *Asian J Androl*; 17(5):742-8.
- Wild R, et al. 2015. Dyslipidemia in pregnancy. *Cardiology clinics*; 33(2): 209-15.
- Wojcik-Baszko D, et al. 2018. Role of dyslipidemia in preeclampsia—A review of lipidomic analysis of blood, placenta, syncytiotrophoblast microvesicles and umbilical cord artery from women with preeclampsia. *Prostaglandins & Other Lipid Mediators*; 139: 19-23.
- Zhao X, et al. 2024. 27-Hydroxycholesterol inhibits trophoblast fusion during placenta development by activating PI3K/AKT/mTOR signaling pathway. *Arch Toxicol*; 98(3):849-863.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.

Lysergic Acid Diethylamide (LSD)

Selected References:

- Breyer-Pfaff U, et al. 1995. Secretion of amitriptyline and metabolites into breast milk. *The American Journal of Psychiatry*; 152(5):812-813.
- Brixen-Rasmussen L, et al. 1982. Amitriptyline and nortriptyline excretion in human breast milk. *Psychopharmacology*; 76:94-95.
- Heinonen OP, et al. 1977. *Birth Defect and Drugs in Pregnancy*. Publishing Sciences Group Inc., Littleton, Mass.
- Huybrechts KF, et al. 2014. Antidepressant use in pregnancy and the risk of cardiac defects. *N Engl J Med*; 370(25):2397-2407.
- Huybrechts KF, et al. 2015. Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension

of the newborn. JAMA; 313(21):2142-2151.

- Kronenfeld, N, et al. 2018. Chronic use of psychotropic medications in breastfeeding women: is it safe?. PloS One, 13(5): e0197196.
- Leutritz AL, et al. 2023. Psychotropic medication in pregnancy and lactation and early development of exposed children. British Journal of Clinical Pharmacology; 89(2):737-750.
- Lusskin SI, et al. 2018. Pharmacotherapy for perinatal depression. Clin Obstet Gynecol; 61(3):544-561.
- Marhofer D, et al. 2021. Schmerztherapie in der Schwangerschaft [Pain management during pregnancy: an expert-based interdisciplinary consensus recommendation.] Schmerz; 35:382-390.
- McElhatton PR, et al. 1996. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Service (ENTIS). Reprod Toxicol; 10:285-294.
- Misri S, Sivertz K. 1991. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psych Med; 21:157-171.
- Nulman I, et al. 1997. Neurodevelopment of children exposed in utero to antidepressant drugs. NEJM; 336(4):258-262.
- Nulman I, et al. 2002. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective controlled study. Am J Psychiatry; 159(11):1889-1895.
- Palmsten K, et al. 2013. Antidepressant use and risk for preeclampsia. Epidemiology; 24(5):682-691.
- Phillips K, et al. 2026. Migraine, associated treatments and risk of miscarriage: a matched cohort study and nested case-control study using the CPRD pregnancy register. Cephalalgia; 46(1):3331024251414634.
- Sarayani A, et al. 2023. Real-world effect of a potential drug-drug interaction between topiramate and oral contraceptives on unintended pregnancy outcomes. Contraception; 120:109953.
- Schoretsanitis G, et al. 2021. Antidepressant transfer into amniotic fluid, umbilical cord blood & breast milk: a systematic review & combined analysis. Prog Neuropsychopharmacol Biol Psychiatry; 107:110228.
- Singh S, et al. 2024. Indian consensus on the role of amitriptyline in migraine prophylaxis. Cureus; 16(2):e54270.
- Suthar N, et al. 2018. Galactorrhea with antidepressants: a case series. Indian Journal of Psychiatry; 60(1):145-146.
- Tamai H, Kinugasa M. 2015. Pregnancy complicated by cyclic vomiting syndrome successfully treated with amitriptyline. Obstet Gynecol; 125(6):1487-1489.
- Tang KY. 2018. Amitriptyline poisoning at 34 weeks of pregnancy. Clin Toxicol (Phila); 56(4):301-303.
- Uguz F. 2017. Poor feeding and severe sedation in a newborn nursed by a mother on low dose amitriptyline. Breastfeed Med; 12:67-68.
- Uguz, F. 2021. A new safety scoring system for the use of psychotropic drugs during lactation. American journal of therapeutics; 28(1):e118-e126.
- Vree PH, et al. 1985. A newborn infant with amitriptyline poisoning. Ned Tijdschr Geneesk; 129(19):910-912.
- Wang XY, et al. 2023. Antidepressant use during pregnancy and the risk for gestational diabetes: a systematic review and meta-analysis. J Matern Fetal Neonatal Med; 36(1):2162817.
- Weissman AM, et al. 2004. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. The American J of Psychiatry; 161(6):1066-1078.
- Yoshida K, et al. 1997. Investigation of pharmacokinetics and possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. J Affective Disord; 43:225-37.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de junio de 2026.